.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The KRONOS trial compared single-inhaler triple therapy with budesonide, glycopyrrolate and formoterol against the corresponding dual therapies in symptomatic patients with moderate-to-very-severe COPD. Unlike studies restricted to patients with a prior exacerbation, KRONOS did not require a recent exacerbation history, making its population relevant to broader everyday COPD management. Over the study period, triple therapy improved lung function compared with the dual-treatment comparators, with effects that varied according to the comparison and endpoint. The trial also demonstrated that benefit from inhaled corticosteroid-containing triple therapy cannot be judged only by exacerbation history. The practical message is more nuanced: treatment should be individualized around symptom burden, airflow limitation, exacerbation risk and the expected incremental benefit of each component. For NAPCON's COPD-focused sessions, KRONOS provides useful evidence for discussing where triple therapy may fit when dual bronchodilation is not enough. It also supports a structured approach to escalation rather than adding inhaled corticosteroid therapy automatically. As with any COPD regimen, clinicians need to balance efficacy with tolerability and the patient's overall risk profile.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The KRONOS trial compared single-inhaler triple therapy with budesonide, glycopyrrolate and formoterol against the corresponding dual therapies in symptomatic patients with moderate-to-very-severe COPD. Unlike studies restricted to patients with a prior exacerbation, KRONOS did not require a recent exacerbation history, making its population relevant to broader everyday COPD management. Over the study period, triple therapy improved lung function compared with the dual-treatment comparators, with effects that varied according to the comparison and endpoint. The trial also demonstrated that benefit from inhaled corticosteroid-containing triple therapy cannot be judged only by exacerbation history. The practical message is more nuanced: treatment should be individualized around symptom burden, airflow limitation, exacerbation risk and the expected incremental benefit of each component. For NAPCON's COPD-focused sessions, KRONOS provides useful evidence for discussing where triple therapy may fit when dual bronchodilation is not enough. It also supports a structured approach to escalation rather than adding inhaled corticosteroid therapy automatically. As with any COPD regimen, clinicians need to balance efficacy with tolerability and the patient's overall risk profile.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
